Deciphera Pharmaceuticals Inc (NQ: DCPH )

42.57 USD UNCHANGED

Streaming Delayed Price Updated: 8:14 AM EST, Jan 28, 2021 Add to My Watchlist

Price and Volume

Volume	154
Open	42.57
Bid (Size)	40.90 (4)
Ask (Size)	46.50 (5)
Prev. Close	42.57
Today's Range	42.57 - 42.57
52wk Range	33.10 - 71.11
Shares Outstanding	36,894,128
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Corporate Milestones

January 11, 2021

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today provided a corporate update...

Deciphera Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 05, 2021

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday,...

Performance

YTD	-24.96%	-24.96%
1 Month	-26.07%	-26.07%
3 Month	-26.74%	-26.74%
6 Month	-7.60%	-7.60%
1 Year	-34.91%	-34.91%

More News

Deciphera Pharmaceuticals Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK® (Ripretinib) in Patients with Second-Line Gastrointestinal Stromal Tumor

November 30, 2020

Deciphera Pharmaceuticals, Inc. to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

November 24, 2020

Medison Pharma Enters Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize QINLOCK® (Ripretinib) in a Multi-Regional Agreement

November 06, 2020

The Boston Globe Names Deciphera a Top Place to Work for 2020

November 23, 2020

New Drug for Gastrointestinal Stromal Tumours (GIST) to be Launched in Australia, New Zealand and South East Asia Following Distribution Agreement

November 05, 2020

Deciphera Presents Data from QINLOCK® (Ripretinib) Program at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting

November 11, 2020

Deciphera Presents Updated Preliminary Data from DCC-3014, its CSF1R Inhibitor Program, in Tenosynovial Giant Cell Tumor Patients at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual M

November 11, 2020

DCPH Crosses Below Key Moving Average Level

January 06, 2021

Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference

November 10, 2020

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.